Crinetics Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 financial results. Additionally, the company announced its CFO will be departing and Oppenheimer lowered its price target on the stock from $74 to $73.
Portfolio Pulse from Benzinga Newsdesk
Crinetics Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 financial results. The company also announced the departure of its CFO, and Oppenheimer lowered its price target on the stock from $74 to $73.
August 09, 2024 | 5:13 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Crinetics Pharmaceuticals shares are trading lower due to worse-than-expected Q2 financial results, the departure of its CFO, and a lowered price target from Oppenheimer.
The combination of poor financial performance, executive departure, and a lowered price target from a major analyst firm is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100